Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older

Philipe Gobeil, Stéphane Pillet, Annie Séguin, Iohann Boulay, Asif Mahmood, Donald C Vinh, Nathalie Charland, Philippe Boutet, François Roman, Robbert Van Der Most, Maria de los Angeles Ceregido Perez, Brian J Ward, Nathalie Landry
doi: https://doi.org/10.1101/2021.05.14.21257248
Philipe Gobeil
1Medicago Inc., 1020 route de l’Église office 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stéphane Pillet
1Medicago Inc., 1020 route de l’Église office 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annie Séguin
1Medicago Inc., 1020 route de l’Église office 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iohann Boulay
1Medicago Inc., 1020 route de l’Église office 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asif Mahmood
1Medicago Inc., 1020 route de l’Église office 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald C Vinh
2Research Institute of the McGill University Health Centre, 1001 Decarie St, Montreal, QC H4A 3J1
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Charland
1Medicago Inc., 1020 route de l’Église office 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Boutet
3GlaxoSmithKline Biologicals SA (Vaccines), Avenue Fleming 20, 1300 Wavre, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Roman
3GlaxoSmithKline Biologicals SA (Vaccines), Avenue Fleming 20, 1300 Wavre, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robbert Van Der Most
4GlaxoSmithKline Biologicals SA (Vaccines), rue de l’Institut 89, 1330 Rixensart, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria de los Angeles Ceregido Perez
3GlaxoSmithKline Biologicals SA (Vaccines), Avenue Fleming 20, 1300 Wavre, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian J Ward
1Medicago Inc., 1020 route de l’Église office 600, Québec, QC, Canada, G1V 3V9
2Research Institute of the McGill University Health Centre, 1001 Decarie St, Montreal, QC H4A 3J1
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Landry
1Medicago Inc., 1020 route de l’Église office 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: landryn@medicago.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The rapid spread of SARS-CoV-2 globally continues to impact humanity on a global scale with rising morbidity and mortality. Despite the development of multiple effective vaccines, new vaccines continue to be required to supply ongoing demand. We report Day 42 interim safety and immunogenicity data from a Phase 2, randomized, placebo-controlled trial in Adults aged 18+ immunized with a virus-like particle vaccine candidate produced in plants displaying SARS-CoV-2 spike glycoprotein (CoVLP) adjuvanted with AS03 (NCT04636697). This report focuses on presenting safety, tolerability and immunogenicity, as measured by neutralizing antibody (NAb) and cell mediated immunity (IFN-γ and IL-4 ELISpot) responses, in Adults aged 18-64 (Adults) and Older Adults aged 65+ (Older Adults). CoVLP adjuvanted with AS03 was well-tolerated and adverse events (AE) were primarily mild or moderate and of transient duration. AEs in Older Adults were more limited than those observed in the Adult population. CoVLP with AS03 induced a significant humoral immune response in both age cohorts. CoVLP with AS03 induced a greater humoral response in Adults than Older Adults after a single dose but this effect was overcome with a second dose when both age cohorts responded with NAb titers that were ∼10-fold higher than those in a panel of sera from patients recovering from COVID-19. A single dose of CoVLP with AS03 induced a significant IFN-γ response in both age cohorts; a second dose significantly boosted IFN-γ and IL-4 responses in both age cohorts. Adults generated a stronger IFN-γ and IL-4 cellular response than did Older Adults after one or two doses of AS03-adjuvanted CoVLP. Safety and immunogenicity from Adults with comorbidities as well as final safety and immunogenicity responses after 12 months will be reported upon availability.

Competing Interest Statement

P. Gobeil, S. Pillet, A. Seguin, I. Boulay, A. Mahmood, N. Charland, B. Ward, and N. Landry are either employees of Medicago Inc. or receive salary support from Medicago Inc. P. Boutet, F. Roman, R. Van Der Most, and M. de los Angeles Ceregido Perez are employees of GlaxoSmithKline.

Clinical Trial

NCT04636697

Funding Statement

The study was sponsored by Medicago Inc.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by a central Research Ethics Review Board (Advarra 372 Hollandview Trail, Suite 300, Aurora, ON L4G 0A5 Canada) as well as the Health Products and Food Branch of Health Canada and was carried out in accordance with the Declaration of Helsinki and the principles of Good Clinical Practices.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Medicago Inc. is committed to providing access to anonymized data collected during the trial that underlie the results reported in this article, at the end of the clinical trial, which is currently scheduled to be 1 year after the last participant is enrolled, unless granted an extension. Medicago Inc. will collaborate with its partners (GlaxoSmithKline, Rixensart, Belgium) on such requests before disclosure. Proposals should be directed to wardb{at}medicago.com or landryn{at}medicago.com. To gain access, data requestors will need to sign a data access agreement and access will be granted for non-commercial research purposes only.

https://www.gisaid.org/

https://www.ncbi.nlm.nih.gov/genbank/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 17, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older
Philipe Gobeil, Stéphane Pillet, Annie Séguin, Iohann Boulay, Asif Mahmood, Donald C Vinh, Nathalie Charland, Philippe Boutet, François Roman, Robbert Van Der Most, Maria de los Angeles Ceregido Perez, Brian J Ward, Nathalie Landry
medRxiv 2021.05.14.21257248; doi: https://doi.org/10.1101/2021.05.14.21257248
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older
Philipe Gobeil, Stéphane Pillet, Annie Séguin, Iohann Boulay, Asif Mahmood, Donald C Vinh, Nathalie Charland, Philippe Boutet, François Roman, Robbert Van Der Most, Maria de los Angeles Ceregido Perez, Brian J Ward, Nathalie Landry
medRxiv 2021.05.14.21257248; doi: https://doi.org/10.1101/2021.05.14.21257248

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (433)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
  • Epidemiology (8982)
  • Forensic Medicine (4)
  • Gastroenterology (419)
  • Genetic and Genomic Medicine (1949)
  • Geriatric Medicine (190)
  • Health Economics (401)
  • Health Informatics (1328)
  • Health Policy (659)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10800)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1825)
  • Nursing (109)
  • Nutrition (272)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (997)
  • Ophthalmology (297)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (579)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1896)
  • Public and Global Health (4120)
  • Radiology and Imaging (675)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (80)